How Antibiotics Work and Why They Stop Working
1. Quick Summary
Antibiotics work through selective toxicity: they interfere with something essential to a bacterium that human cells either do not have or have in a different form. Cell wall construction, bacterial ribosomes and bacterial DNA replication enzymes are the usual targets.
Resistance is evolution under that pressure. Any treatment kills the susceptible bacteria and leaves behind those that happen to survive, and those survivors multiply. The population shifts, and the drug stops working.
2. What It Means
Different classes hit different machinery. Some prevent bacteria from building their cell wall, so the cell bursts as it grows. Others bind to bacterial ribosomes and stop protein production. Others interfere with enzymes that bacteria need to copy their DNA or to make folate.
Selective toxicity is why these drugs are usable at all. Human cells have no cell wall, and human ribosomes and replication enzymes differ enough from bacterial ones that a drug can discriminate. When that discrimination is imperfect, side effects follow.
Resistance arrives through several routes. Bacteria can produce enzymes that destroy the drug, change the shape of the target so it no longer binds, pump the drug back out before it accumulates, or reduce their wall’s permeability so less of it enters.
3. Why It Happens
Bacteria evolve fast because they reproduce fast. A population in an infection can go through hundreds of generations during a course of treatment, and each generation is an opportunity for a useful mutation to appear and be selected.
They also share genes horizontally. Resistance can be carried on small pieces of DNA that pass between bacteria directly, including between unrelated species, which is why resistance can spread through a hospital or a farm much faster than mutation alone would allow.
The pressure comes from exposure. Using an antibiotic applies selection to every bacterium in the body that the drug reaches, not only the ones causing the illness, so resistant strains can be selected in bacteria that were doing no harm.
Incomplete courses are a real problem but not the main one. Taking an antibiotic when it is not needed at all, and using broad-spectrum drugs where a narrow one would do, applies selection without any corresponding benefit.
4. Real Examples
The reason antibiotics do nothing for a cold is that colds are viral. Viruses use the host cell’s machinery to replicate and have none of the structures these drugs target, so there is nothing for the drug to attack and the only effect is selection on your bacteria.
Hospital-acquired infections show the outcome clearly. Strains resistant to multiple drug classes emerged in healthcare settings first and have since spread into the community, and some infections now require drugs that were previously held in reserve.
Agricultural use matters for the same reason. Antibiotics used routinely in livestock apply selection on a very large scale, and resistant organisms can reach people through food, water and direct contact.
5. How It Affects Us
The consequences are already measurable. Routine procedures that depend on preventing infection, including surgery and chemotherapy, become riskier as the drugs that make them safe become less reliable.
New drug development has not kept pace, and the economics explain why. Antibiotics are taken for short courses, are curative rather than chronic, and are deliberately held back to preserve effectiveness, which makes them a poor commercial prospect compared with long-term medications.
For individuals the practical guidance is narrow and consistent: take antibiotics when they are prescribed for a bacterial infection, complete the course as directed, and do not press for them when the illness is viral.
6. Key Takeaways
- Antibiotics exploit differences between bacterial and human cells, which is why they do nothing for viruses.
- Resistance arises through mutation and, importantly, through bacteria sharing resistance genes directly.
- Any exposure selects for resistance, so unnecessary use carries cost without benefit.
- The pipeline for new antibiotics is thin, partly because short curative courses are poor commercial prospects.